Table 1.
Baseline Characteristics of Study Patients (n=39).
| Variables | Control (N=19) N (%) | Intervention (N=20) N (%) | P |
|---|---|---|---|
| Admission service | 0.230 | ||
| INFa | 9 (47.4) | 14 (70) | |
| MINb | 2 (10.5) | 2 (10) | |
| Others | 6 (31.57) | 4 (20) | |
| Duration of hospital stay (days) | 7.0 (5.0-13.0) | 9.5 (6.0-15.8) | 0.160 |
| Stratification level | 0.683 | ||
| N1 | 4 (21.1) | 3 (15.0) | |
| N2 | 4 (21.1) | 7 (35.0) | |
| N3 | 11 (57.9) | 10 (50.0) | |
| ARTc type | 0.810 | ||
| ITIANd + ITINNe | 6 (31.6) | 4 (20.0) | |
| ITIAN + 1If | 2 (10.5) | 2 (10.0) | |
| ITIAN + ININ | 7 (36.8) | 7 (35.0) | |
| Others | 4 (21.1) | 7 (25.0) | |
| Polypharmacy | 9 (39.1) | 14 (60.9) | 0.200 |
| MRCIh | |||
| ART | 3.9 (± 0.9) | 4.4(± 1.5) | 0.280 |
| co-ART' | 11.6 (± 2.8) | 13.4 (± 5.4) | 0.200 |
| Global | 15.5 (± 3.1) | 17.7 (± 6.1) | 0.153 |
| Adherence (%) | |||
| ART | 63.2 | 60 | 1.000 |
| co-ART | 26.3 | 35 | 0.369 |
| Global | 47.4 | 35 | 0.523 |
| Controlled disease (CD4 Count > 200cel/mcL and Undetectable viral load) | 11 (57.9) | 11 (55%) | 0.556 |
| RCVj [median (interquartile range)] | 7 (5-14) | 9.5 (2.4-12.8) | 0.772 |
| Smoking patients | 14 (73.7) | 12 (60) | 0.286 |
| Patient with alcohol consume | 7 (36.8) | 6 (30) | 0.455 |
| Patient with drug consume | 4 (21.2) | 7 (35) | 0.271 |
a
Infectious; bInternal medicine; cAntiretroviral treatment; dNucleoside reverse transcriptase inhibitor; eNon-nucleoside reverse transcriptase inhibitor; fProtease inhibitor; gIntegrase inhibitor; hMedication regimen complexity index;iConcomitant Medication; jCardiovascular risk.